Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725292 | 0.86 | L3MBTL3 (0.71) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL10395267 | 0.84 | L3MBTL3 (0.73) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL3767914 | 0.83 | HRH3 (0.51) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL5209493 | 0.83 | HRH3 (0.60) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL5214091 | 0.82 | HRH3 (0.59) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL5800431 | 0.81 | KDM4E (0.61) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL7315490 | 0.81 | L3MBTL3 (0.50) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL7989190 | 0.79 | L3MBTL3 (0.54) | HRH3MEN1L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL6538634 | 0.78 | KDM4E (0.53) | HRH3KDM4ETP53GPR119KCNH2 | |
| SCHEMBL22848341 | 0.78 | KDM4E (0.50) | HRH3MEN1L3MBTL3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743776-B2 | ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | HRH3 2167/4885MEN1 2457/4885L3MBTL3 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.